Overview

Trial of Intravenous Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants

Status:
Completed
Trial end date:
2020-11-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether intravenous azithromycin is effective in eradicating Ureaplasma respiratory tract infection in preterm infants born at 24 to 28 weeks gestation.
Phase:
Phase 2
Details
Lead Sponsor:
Rose Viscardi
University of Maryland, Baltimore
Collaborators:
Christiana Care Health Services
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Johns Hopkins University
Mercy Medical Center
University of Alabama at Birmingham
University of Virginia
Treatments:
Azithromycin